Last reviewed · How we verify
A3
A3 is a medication that works by inhibiting the renin-angiotensin system.
A3 is a medication that works by inhibiting the renin-angiotensin system. Used for Hypertension, Heart failure.
At a glance
| Generic name | A3 |
|---|---|
| Also known as | Equatir 10 T10/C10 - CBD 10%, THC 10% |
| Sponsor | Breath of Life International Pharma Ltd |
| Drug class | Angiotensin receptor blocker |
| Target | AT1 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
A3 is an angiotensin receptor blocker (ARB) that blocks the action of angiotensin II, a potent vasoconstrictor, thereby reducing blood pressure and decreasing the workload on the heart.
Approved indications
- Hypertension
- Heart failure
Common side effects
- Dizziness
- Headache
- Cough
- Fatigue
- Nausea
Key clinical trials
- Rosacea and Ivermectin (PHASE2)
- Safety and Efficacy Study of BRIMOCHOL™, BRIMOCHOL™ F, and Carbachol in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia (PHASE2)
- Living With Multimorbidity: Care Coordination and Symptom Management Program (COORDINATE) (NA)
- Individualized Precision Isavuconazole Therapy Guided by PK/PD Principles for the Geriatric Population
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (PHASE2)
- A Study of B-3E07 and Forsteo® in Healthy Adult Female Participants (PHASE1)
- Efficacy of Physical Fitness Training Combined With Exercise Therapy on Gait in Children With Cerebral Palsy
- A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |